Newer NNRTI with cleaner DDI profile (CYP3A4 substrate but minimal induction). Lower psychiatric side effect signal than efavirenz. Used in DOR/3TC/TDF (Delstrigo) once-daily regimen.
Half-Life & Elimination Curve (PO: 15h)
Plasma (PO)t½ Decay (15h)
0×t½0h100%(0.837 mg/L)
1×t½15h50%(0.418 mg/L)
2×t½30h25%(0.209 mg/L)
3×t½45h12.5%(0.105 mg/L)
4×t½60h6.3%(52.3 µg/L)
5×t½3.1d3.1%(26.2 µg/L)
Elimination t½15h (PO)
Rate Constant (ke)0.0462 h⁻¹
Time to Peak (Tmax)5.25h
Est. Peak (Cmax)0.837 mg/L
Clearance (CL)2.77 L/h
97% Washout (5×t½)3.1d
Dosing Guidelines
Oral (PO): Typical 100 mg
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 64% · Volume of Distribution (Vd): 60 L · Absorption (ka): 0.5 h⁻¹ (t½ka ≈ 1.39h) [PMID 29723418]